文献速递眼底病与葡萄膜炎

局部干扰素α2b辅助治疗糖尿病黄斑水肿的随机对照试验

EVALUATION OF THE EFFECT OF TOPICAL INTERFERON α2b AS A COMPLEMENTARY TREATMENT OF MACULAR EDEMA OF PATIENTS WITH DIABETIC RETINOPATHY: A Double-Blind Placebo-Controlled Randomized Clinical Trial Study.
PubMed 文献 · Retina · 2020-01-01

这项双盲安慰剂对照随机临床试验纳入50例糖尿病黄斑水肿患者(每例一眼),随机接受局部干扰素α2b 1 MU/mL或人工泪液辅助治疗。结果显示干扰素组第4周和第8周最佳矫正视力改善优于人工泪液组,但黄斑中心厚度变化无统计学差异,且干扰素组第4周眼压下降,未发现明显副作用。

要点

  • 局部干扰素α2b辅助治疗可改善糖尿病黄斑水肿患者第4周和第8周的最佳矫正视力。
  • 黄斑中心厚度在两组间第4周和第8周的变化均无统计学显著差异。
  • 干扰素组第4周眼压下降,人工泪液组略升,差异有统计学意义。

核心结论

  • 局部干扰素α2b 1 MU/mL耐受良好,可能改善糖尿病黄斑水肿患者的最佳矫正视力,并具有降低眼压的作用,但需进一步研究证实。

研究设计与样本

  • 双盲安慰剂对照随机临床试验,纳入50例糖尿病黄斑水肿患者的50只眼(每例一眼),随机分为局部干扰素α2b 1 MU/mL组或人工泪液组作为辅助治疗。

主要发现

  • 第4周最佳矫正视力改善干扰素组为6.85个ETDRS字母,人工泪液组为1.45个字母,P=0.001。
  • 第8周最佳矫正视力改善干扰素组为6.75个ETDRS字母,人工泪液组为1.05个字母,P=0.005。
  • 第4周黄斑中心厚度变化干扰素组为53.1±153 µm,人工泪液组为26.6±119.1 µm,P=0.497。
  • 第8周黄斑中心厚度变化干扰素组为27.9±67.7 µm,人工泪液组为29.2±98 µm,P=0.957。
  • 第4周眼压变化干扰素组下降1.7±3 mmHg,人工泪液组升高0.1±2.3 mmHg,P=0.018,未检测到明显副作用。

临床怎么用

  • 局部干扰素α2b 1 MU/mL可作为糖尿病黄斑水肿的辅助治疗选择,可能改善短期视力并降低眼压,但黄斑厚度改善不显著,需个体化评估。

局限性

  • 本研究仅评估短期效果,样本量较小(50眼),黄斑中心厚度变化无统计学差异,结论需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study is to evaluate the effect of the topical interferon α2b (IFNα2b) as an adjunctive therapy in the treatment of diabetic macular edema. METHOD: This was a randomized controlled clinical trial performed on patients with diabetic macular edema. Fifty eyes of 50 patients (one eye/patient) who were receiving treatment for diabetic macular edema were randomly assigned to get topical IFNα2b 1 MU/mL or artificial tear eye drop as an adjunctive therapy. The primary measure outcomes were best-corrected visual acuity and central macular thickness; the secondary goals were to assess the effect of topical IFNα2b on the intraocular pressure and its potential side effects. RESULTS: Baseline demographic data of the two groups were similar. The improvement in visual acuity of patients on IFN was more than the patients on artificial tear by the end of the fourth week (6.85 and 1.45 Early Treatment Diabetic Retinopathy Study letters, respectively, P = 0.001) and the eighth week (6.75 and 1.05 Early Treatment Diabetic Retinopathy Study letters, respectively, P = 0.005). The central macular thickness was also decreased correspondingly by the end of fourth week (53.1 ± 153 µm for patients on IFN and 26.6 ± 119.1 µm for patients on artificial tear, P = 0.497) and eighth week (27.9 ± 67.7 for patients on IFN and 29.2 ± 98 µm for patients on artificial tear, P = 0.957), but it was not statistically significant. Intraocular pressure was decreased on the fourth week in IFN group for 1.7 mmHg ±3 and increased for 0.1 mmHg ±2.3 in the artificial tear group (P = 0.018). No significant side effect was detected with topical IFN drop. CONCLUSION: This study evaluated the short-term effects of topical IFNα2b 1 MU/mL. The drug was well tolerated and may have an effect on improvement of best-corrected visual acuity in patients with diabetic macular edema. It also had an intraocular pressure lowering effect on the studied eyes. However, further studies are needed to confirm this finding.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Afarid M, Meshksar A, Salehi A, et al. EVALUATION OF THE EFFECT OF TOPICAL INTERFERON α2b AS A COMPLEMENTARY TREATMENT OF MACULAR EDEMA OF PATIENTS WITH DIABETIC RETINOPATHY: A Double-Blind Placebo-Controlled Randomized Clinical Trial Study. Retina. 2020. PMID: 30839494. doi:10.1097/IAE.0000000000002465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。